Share This Article:

Risk Factors for Drug-Resistant Tuberculosis

Abstract Full-Text HTML Download Download as PDF (Size:2495KB) PP. 111-118
DOI: 10.4236/jtr.2014.23014    4,198 Downloads   5,595 Views   Citations

ABSTRACT

Objective: Drug resistance is considered one of the main threats for tuberculosis control. Our aim was to identify risk factors for drug resistance in tuberculosis patients in the Northern Portugal. Study Design and Methods: Retrospective case-control study. The medical records and drug susceptibility test data from TB patients diagnosed between 31 March 2009 and 1 April 2010 were examined. We enrolled 119 patients with any drug resistance to first line anti-TB drugs and 238 with drug-susceptible TB, matched by age group. Variables analyzed included: gender, country of origin, employment situation, site of disease, previous treatment, presence of diabetes mellitus, HIV infection, alcohol abuse, intravenous drug use, abuse of other drugs and smoking habits. Multivariate conditional logistic regression was used to identify independent predictors for drug-resistant TB. Results: Diabetes mellitus [adjusted odds ratio (OR): 3.54; 95% CI: 1.45 - 8.66], intravenous drug use (OR: 4.77; 95% CI: 1.24 - 18.32) and previous TB treatment (OR: 2.48; 95% CI: 1.12 - 5.49) were found to be risk factors for drug-resistant disease development. Conclusions: Diabetes mellitus, prior tuberculosis treatment, and intravenous drug use were risk factors for drug-resistant disease. The association between diabetes and drug-resistant TB should be further explored. Identifying clinical predictors of drug resistance can allow prompt identification of patients at risk for drug-resistant TB.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Gomes, M. , Correia, A. , Mendonça, D. and Duarte, R. (2014) Risk Factors for Drug-Resistant Tuberculosis. Journal of Tuberculosis Research, 2, 111-118. doi: 10.4236/jtr.2014.23014.

References

[1] World Health Organization (WHO) (2010) The Global Plan to Stop TB 2011-2015. World Health Organization, Geneva.
[2] World Health Organization (WHO) (2010) Multidrug and Extensively Drug-Resistant TB (M/XDR-TB)-2010. Global Report on Surveillance and Response. World Health Organization, Geneva.
[3] European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe (2014) Tuberculosis Surveillance in Europe 2009. Stockholm, European Centre for Disease Prevention and Control, 2011. http://www.ecdc.europa.eu
[4] Direcção Geral de Saúde (2011) Programa Nacional de Luta contra a Tuberculose. Ponto de situação epidemiológica e de desempenho. Divisão de Doenças Transmissíveis.
[5] Administração Regional da Saúde no Norte, I.P. A Tuberculose na Região de Saúde do Norte 2000-2010. Ano 2011. Unidade de Vigilancia Epidemiológica.
[6] Programa Nacional de Luta contra a Tuberculose. Perfil de susceptibilidade aos antibióticos de estirpe Mycobacterium Tuberculosis—Sistema de notificação laboratorial 2009. Ano 2010. Administração Regional de Saúde do Norte.
[7] Yang, X., Li, Y., Wen, X., Wu, X. and Li, X. (2010) Risk Factors for Drug Resistance in Pulmonary Tuberculosis in Patients. JEBM, 3, 162-167.
[8] Caminero, J.A. (2010) Multidrug-Resistant Tuberculosis: Epidemiology, Risk Factors and Case Finding. International Journal of Tuberculosis and Lung Disease, 14, 382-390.
[9] Farazi, A., Sofian, M., Zarrinfan, N., Katebi, F., Hoseini, S. and Keshavarz, R. (2013) Drug Resistance Patterns and Associated Risk Factors of Tuberculosis in the Central Province of Iran. Caspian Journal of Internal Medicine, 4, 785-789.
[10] Suárez-Garcia, I., Rodrígues-Blanco, A., Vidal-Pérez, J.L., García-Viejo, M.A., Jaras-Hernandez, M.J., López, O., et al. (2009) Risk Factors for Multidrug—Resistant Tuberculosis in a Tuberculosis Unit in Madrid, Spain. European Journal of Clinical Microbiology Infectious Diseases, 28, 325-330.
http://dx.doi.org/10.1007/s10096-008-0627-y
[11] Faustini, A., Hall, A.J. and Perucci, C.A. (2006) Risk Factors for Multidrug Resistant Tuberculosis in Europe: A Systematic Review. Thorax, 61, 158-163. http://dx.doi.org/10.1136/thx.2005.045963
[12] Casal, M., Vaquero, M., Rinder, H., Tortoli, E., Grosset, J., Rusch-Gerdes, S., et al. (2005) A Case-Control Study for Multidrug-Resistant Tuberculosis: Risk Factors in Four European Countries. Microbial Drug Resistance, 11, 62-67. http://dx.doi.org/10.1089/mdr.2005.11.62
[13] Kliiman, M.D. and Altraja, A. (2009) Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis. Annals of Internal Medicine, 150, 766-775.
http://dx.doi.org/10.7326/0003-4819-150-11-200906020-00004
[14] Lomtadze, N., Aspindzelasvili, R., Janjgava, M., Mirtskhulava, V., Wright, A., Blumberg, H.M. and Salakaia, A. (2009) Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Republic of Georgia: A Population Based Study. The International Journal of Tuberculosis and Lung Disease, 13, 68-73.
[15] Liu, Q., Zhu, L., Shao, Y., Song, H., Li, G., Zhou, Y., et al. (2013) Rates and Risk Factors for Drug Resistance Tuberculosis in Northeastern China. BMC Public Health, 13, 1171.
http://dx.doi.org/10.1186/1471-2458-13-1171
[16] Flora, M.S., Amin, M.N., Karim, M.R., Afros, S., Islam, S., Alam, A., et al. (2013) Risk Factors of Multi-Drug-Resistant Tuberculosis in Bangladeshi Population: A Case Control Study. Bangladesh Medical Research Council Bulletin, 39, 34-41. http://dx.doi.org/10.3329/bmrcb.v39i1.15808
[17] Wang, K., Chen, S., Wang, X., Zhong, J., Wang, X., Huai, P., et al. (2014) Factors Contributing to the High Prevalence of Multidrug-Resistant Tuberculosis among Previously Treated Patients: A Case-Control Study from China. Microbial Drug Resistance, 20, 294-300.
[18] World Health Organization. (2009) Guidelines for Surveillance of Drug Resistance in Tuberculosis. 4th Edition, WHO, Geneva.
[19] Alisjahbana, B., Sahiratmadja, E., Nelwan, E.J., Purwa, A.M., Ahmad, Y., Ottenhoff, T.H., et al. (2007) The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary Tuberculosis. Clinical Infectious Diseases, 45, 428-435. http://dx.doi.org/10.1086/519841
[20] Dooley, K. and Chaisson, R. (2009) Tuberculosis and Diabetes Mellitus: Convergence of Two Epidemics. The Lancet Infectious Diseases, 9, 737-746. http://dx.doi.org/10.1016/S1473-3099(09)70282-8
[21] Harries, A., Lin, Y., Satyanarayana, S., Lonnroth, K., Li, L., Wilson, N., et al. (2011) The Looming Epidemic of Diabetes-Associated Tuberculosis: Learning Lessons from HIV-Associated Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 15, 1436-1444. http://dx.doi.org/10.5588/ijtld.11.0503
[22] Maurice, J. (2011) WHO Framework Target Tuberculosis-Diabetes Link. The Lancet, 378, 1209-1210. http://dx.doi.org/10.1016/S0140-6736(11)61527-4
[23] Baker, M., Harries, A., Jeon, C., Hart, J., Kapur, A., Lonnroth, K., et al. (2011) The Impact of Diabetes on Tuberculosis Treatment Outcomes: A Systematic Review. BMC Medicine, 9, 81.
http://dx.doi.org/10.1186/1741-7015-9-81
[24] Mi, F., Tan, S., Liang, L., Harries, A., Hinderaker, S., Lin, Y., et al. (2013) Diabetes Mellitus and Tuberculosis: Patterns of Tuberculosis, Two-Month Smear Conversion and Treatment Outcomes in Guangzhou, China. Tropical Medicine and International Health, 18, 1379-1385.
http://dx.doi.org/10.1111/tmi.12198
[25] Mdivani, N., Zangaladze, E., Volkova, N., Kourbatova, E., Jibuti, T., Shubladze, N., et al. (2008) High Prevalence of Multidrug-Resistant Tuberculosis in Georgia. International Journal of Infectious Diseases, 12, 635-644. http://dx.doi.org/10.1016/j.ijid.2008.03.012
[26] Duarte, R., Santos, A., Mota, M., Carvalho, A., Marques, A. and Barros, H. (2011) Involving Community Partners in the Management of Tuberculosis among Drug Users. Public Health, 125, 60-62.
http://dx.doi.org/10.1016/j.puhe.2010.09.002
[27] Deiss, R., Rodwell, T. and Garfein, R. (2009) Tuberculosis and Drug Use: Review and Update. Clinical Infectious Diseases, 48, 72-82. http://dx.doi.org/10.1086/594126
[28] Moonan, P., Quituga, T., Pogoda, J., Woo, G., Drewyer, G., Sahbazian, B., et al. (2011) Does Directly Observed Therapy (DOT) Reduce Drug Resistant Tuberculosis? BMC Public Health, 11, 19.
http://dx.doi.org/10.1186/1471-2458-11-19

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.